The relatively recent FDA approvals of tedizolid (Merck’s Sivextro), dalbavancin (Allergan’s Dalvance), and oritavancin (The Medicines Company’s Orbactiv) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) highlight the competitive nature of the hospital-treated MRSA market. Further, with the recent generic availability of the key anti-MRSA agents linezolid (Pfizer’s Zyvox) and daptomycin (Merck’s Cubicin), new and older brands will need to offer improvements in key areas of differentiation to gain uptake in this crowded market. This report analyzes the current and anticipated MRSA inpatient treatment landscape, providing critical information for manufacturers to position their products based on attributes that differentiate them from the competition to maximize uptake in the high-value hospital market segment.

QUESTIONS ANSWERED

  •  What percentage of patients receive empiric treatment covering MRSA in eight common indications, including ABSSSI and osteomyelitis? What is the success rate of empiric treatment for these MRSA patients?
  • What are the most prescribed first-, second-, and third-line anti-MRSA therapies for inpatients with ABSSSI, bloodstream infection, nosocomial pneumonia, and community-acquired bacterial pneumonia? What are the patients shares for key anti-MRSA agents in these indications?
  • What are the percentages of MRSA patients who are ineligible for different key anti-MRSA agents? What are the common reasons that MRSA patients are ineligible for linezolid and daptomycin?
  •  What are the physician-reported drivers and constraints determining current prescribing patterns and recent/anticipated changes?

Table of contents

  • Detailed, Expanded Analysis (US)
    • Introduction to Current Treatment for MRSA
      • Key Findings
      • Summary Figures
      • Introduction to Current Treatment and Medical Practice for MRSA
    • Physician Prescribing Practices
      • Key Findings
      • Patient Characteristics
        • BSIs, Osteomyelitis, and Implanted Medical Device Infections Are Common Difficult-to-Treat HT-MRSA Infections
      • Treatment Practices
        • Opportunities Exist for Later-Line Antibiotics with Benefits in Safety and Convenience
        • Time to Treatment Start
        • Treatment Rates
        • Patient Share by Product
        • Treatment Duration by Product
        • Use of Nonpharmacological Approaches (optional)
        • Line of Therapy Analysis
        • Combination/Regimen/Comedication Analysis
      • Persistency and Compliance
        • Persistency and Compliance Rates Are High Among Hospitalized MRSA Patients
      • Sequencing of Treatment
        • Oral Linezolid Is a Top Choice for Discharging MRSA Patients on Treatment
      • Recent/Anticipated Changes in Brand Use/Treatment Approach
    • Physician Insight on Medical Practice
      • Key Findings
      • Drivers of Treatment Selection
        • Overall Cost of Treatment Is a Major Driver for Antibiotic Selections in the HT-MRSA Market
        • Factors Influencing Treatment and Disease Management
        • Major Drivers of Brand Use/Treatment
        • Major Obstacles to Brand Use/Treatment
        • Treatment Failure/Brand Issues
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Primary Market Research

Author(s): Jiamin Zhuo, PhD

Jiamin Zhuo, is a business insights analyst on the infectious, niche, and rare diseases team at Decision Resources Group. He provides expert insight into the commercial aspects of drug development and market dynamics in bacterial infections, including gram-negative infections and Methicillin-resistant Staphylococcus aureus . He attained his at the Mayo Graduate School, Mayo Clinic, in Minnesota and his in physiology from Peking University in China. Prior to joining DRG, Dr. Zhuo was a postdoctoral fellow at Boston University and MIT, where he gained extensive experience in quantitative research methods.